Participant flow

Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer · Source last updated 2019-08-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Ixabepilone administered at 40 mg/m2 IV infusion over 3 hours on day 1 of a 21-day cycle until disease progression or adverse effects prohibit further treatment

   id

   FG000

   title

   Ixabepilone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible-Second primary cancer site

   2. reasons

      1. group Id

         FG000

         num Subjects

         6

      type

      Ineligible- Wrong cell type

   3. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible-Inadequate pathology

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         42

      type

      STARTED

   2. achievements

      1. comment

         Eligible and treated patients

         group Id

         FG000

         num Subjects

         34

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study was activated on 9/7/2010 and closed to accrual on 8/26/2013 (suspended from 3/5/2012 to 9/30/2012).

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice